Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Operating Expenses:
Research and development	$ 2,038	$ 2,262
General and administrative	2,554	2,897
Total operating expenses	4,592	5,159
Operating loss	(4,592)	(5,159)
Other income (expense):
Investment income, net	227	178
Interest expense	0	(3)
Total other income (expense), net	227	175
Net loss	(4,365)	(4,984)
Less - net income (loss) attributable to noncontrolling interests	2	(2)
Net (loss) income attributable to Caladrius Biosciences, Inc. common stockholders	$ (4,367)	$ (4,982)
Basic and diluted loss per share
Caladrius Biosciences, Inc. common stockholders (in usd per share)	$ (0.44)	$ (0.52)
Weighted average common shares outstanding
Basic and diluted shares	10,027	9,557